DGAP-News: Neovacs S.A. / Key word(s): Conference Neovacs to Present at Bio International Convention 2016 30.05.2016 / 08:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PRESS RELEASE Neovacs to Present at Bio International Convention 2016 Paris and Boston, May 30th, 2016 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Bio International Convention, one of the major international conventions focused on the biotechnology industry, being held June 6 to 9, 2016, in San Francisco, CA. The Convention brings together established and emerging leaders in the global biotechnology and pharmaceutical industry. In a presentation on Monday, June 6, at 2:30pm PDT (UTC-7 pm), Miguel Sieler, CEO of Neovacs will discuss the Company's proprietary Kinoid technology, providing updates about Neovacs' pipeline and strategic development programs for 2016/2017. He will also be accompanied by two members of the scientific management team: Dr Thérèse Croughs, Chief Medical officer, and Geraldine Vogel, Scientific Director of Neovacs. "We are pleased to participate in this event, which is an excellent opportunity to meet other major companies from our industry," commented Miguel Sieler, CEO of Neovacs. "This year, our participation will be more significant, as we obtained IND approval from the Food and Drug Administration in the United States for our Phase IIb study of IFNα-Kinoid in the treatment of Lupus, which allows us to broaden our visibility and increase the interest in our technology platform." Meet Neovacs' team at booth #413, South & North Hall of the Moscone Center in San Francisco, California, USA About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com --------------------------------------------------------------------------- 30.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service --------------------------------------------------------------------------- 467283 30.05.2016
DGAP-News: Neovacs to Present at Bio International
Top 10 Most Recent News Articles
Doximity's Legal Woes: Class Action Deadline Looms
The Truth Behind Doximity's Promises The brass tacks of investing often boil down to trust—a commodity that's now in short supply over at Doximity, Inc. (NYSE: DOCS). Investors have been left hanging after promises of lucrative engagement signals turned out to be a mere pipe dream. Levi & Korsinsky, LLP sounds the alarm on what's shaping up to be a high-stakes class...
Continue Reading
DAN, GPRO, PSNL Deals Under Investor Scrutiny
Behind the Curtain: What Do These Deals Mean for Shareholders? Sometimes, investing in a stock ain't just about numbers on a screen—it's about untangling the whole messy ball of yarn these companies hand you with a smile. We're looking at Dana Incorporated (NYSE: DAN), GoPro, Inc. (NASDAQ: GPRO), and Personalis, Inc. (NASDAQ: PSNL). They've all got deals on the table,...
Continue Reading
Fluence Energy Lawsuit: Investor Unrest Unleashed
The Turbulence Behind FLNC: A Hard Pill to Swallow Looks like Fluence Energy (NASDAQ: FLNC) has stumbled right into a mess that's leaving investors with a bitter aftertaste. A securities class action lawsuit has been thrown their way, shaking up any stability folks thought they had. Levi & Korsinsky, LLP laid down the gauntlet on behalf of the shareholders hoodwinked by...
Continue Reading
Gilbert Welcomes Luxury Florals: French Florist Expands
A Fresh Bloom in Gilbert: French Florist Steps In Toss aside your preconceived notions of what a florist shop should be. When French Florist sets up shop, it's not just about selling flowers—they’re a game-changer in the floral industry. As of November 4, they've stamped their luxury mark in Gilbert, Arizona, courtesy of Ronny and Nicole Record, who aren’t your...
Continue Reading
Parloa and OpenAI Expand AI Customer Service Partnership
AI Agents: A New Frontier in Customer Service The world of customer service is about to see a major shake-up, folks. Parloa, with its roots deep in AI customer service innovation, and tech powerhouse OpenAI are teaming up to expand their partnership. This isn’t some pie-in-the-sky dream; this is about bringing real-life improvements to how businesses and customers...
Continue Reading
Madrigal Faces Troubling Whistleblower Claims
Whistleblower Complaint Rocks Madrigal Let me tell you, today's chatter isn't for the faint-hearted investor. Madrigal Pharmaceuticals (NASDAQ: MDGL) is under scrutiny, and it's making waves. The gears started turning when their former Senior VP and Head of Clinical Development unloaded a bombshell: he reported dirt on Madrigal's safety and efficacy data for Rezdiffra,...
Continue Reading
Nektar Gears Up for Key November Investor Engagements
Nektar Therapeutics on the Investor Radar Here's the scoop in the biotech world: Nektar Therapeutics, that clinical-stage biotech pioneer, is stepping into the spotlight at not one, but two heavyweight investor gigs this November. Showcasing their hand not just means they'll draw the curtains on their groundbreaking pipeline, but it's a shot across the bow to remind us...
Continue Reading
Clarivate's Upcoming Conference Presentation: What to Expect
Conference Time: Will Clarivate Deliver the Goods? Grab your calendars, folks. November 18 is when Clarivate Plc is stepping into the spotlight at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference. Their bigwigs, Matti Shem Tov, the CEO, and Michael Easton, the CFO, will be there to spill the beans. They’re set to take the mike...
Continue Reading
MyyShop Poised to Redefine the Creator Economy
Breaking Ground in Creator Ecosystems MyyShop isn't just a player in the creator economy; it's trying to change the damned rules. By focusing intensely on co-creation and learning, MyyShop's putting its chips on creating an inclusive and sustainable space where creators aren't just participants but the ones calling the shots. Catalyzing Co-Creation Everybody in the game...
Continue Reading
VTech's Revenue Jump: Profit Margins Slip Amid Cost Surge
Charting VTech's Financial Waters Well, here we are – another chapter in the saga of VTech, the electronic learning product titan. This time, they've danced a jig of higher revenues, a sweet 5.6% jump to $1,046.9 million for the six months leading to September 2026. But hang on, the party's not all balloons and confetti. Profit margins? They're bobbing like a ship in a...
Continue ReadingTop 5 Most Recently Viewed Articles
Assurant Stock Analysis: Navigating a 52-Week Low
Assurant Stock Hits 52-Week Low In the midst of evolving market conditions, Assurant Inc. (NYSE: AIZ) has seen its stock price drop to a notable 52-week low of $19.85. This decline translates to a 1-year change of -2.2%, prompting investors to reassess their strategies. However, amid this downturn, Assurant continues to exhibit robust fundamentals, evidenced by its...
Continue Reading
Ona Therapeutics Boosts Leadership to Propel Innovative Cancer Treatments
Ona Therapeutics Strengthens Leadership Team for Innovative Cancer Therapies Ona Therapeutics is making waves in the biotech industry with its recent strategic leadership appointments aimed at fast-tracking the development of innovative antibody-drug conjugates (ADCs). These ADCs are designed to target and destroy hard-to-treat cancer cells across various solid tumor...
Continue Reading
The Exciting Return of NJ Digital Marketing Conference 2025
New Jersey Digital Marketing Conference is Back! Mark your calendars for the much-anticipated return of the New Jersey Digital Marketing Conference (NJDMC) on October 23, 2025, at the historic Bell Works campus. This vibrant event aims to unite innovative marketers, industry leaders, and creative thinkers for an inspiring day filled with learning and networking. A Day of...
Continue Reading
Hancock Health Partners with Revology for Enhanced Revenue Operations
Hancock Health Partners with Revology for Enhanced Revenue Operations Hancock Health is excited to announce its partnership with Revology aimed at transforming its revenue cycle management (RCM) operations. This collaboration marks a significant step towards adopting advanced technology that promises to improve efficiency and transparency in the billing processes....
Continue Reading
Middlefield Canadian Income PCC: Insights on Share Value
Middlefield Canadian Income PCC Overview Middlefield Canadian Income PCC, a respected entity in the financial sector, has been gaining attention among investors. This protected cell company, incorporated in Jersey with registration number 93546, operates under the legal entity identifier 2138007ENW3JEJXC8658. Known for its strategic investments, the company focuses on...
Continue Reading